
I have migrated to blue sky. bsky.app/profile/ryanet.bsky…

Associate Professor of Orthopaedic Surgery. Bones are best.

I have migrated to blue sky. bsky.app/profile/ryanet.bsky…

To switch to Bluesky, simply sign up at bsky.app, create an account, and then use the Sky Follower Bridge Chrome extension to migrate your Twitter follows and blocks. sky-follower-bridge.dev/get-…
I have migrated to blue sky. bsky.app/profile/ryanet.bsky…


"The U.S. needs more scientists, engineers and other technical talent. These firings will cause many of them to leave the field." npr.org/2025/02/18/nx-s1-530…

Consider getting involved tomorrow: fiftyfifty.one/

Wow! What a debate. Thanks to both debaters and congratulations to the victor: @mmcgeelawrence
#ORS2025 Debate is Underway!


Last year, $9B of the $35B that the National Institutes of Health (NIH) granted for research was used for administrative overhead, what is known as “indirect costs.” Today, NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%, above what many major foundations allow and much lower than the 60%+ that some institutions charge the government today. This change will save more than $4B a year effective immediately.

Very successful OpenDoor event at #ORS2025. Congratulations to co-chairs @JasonCMarvin and Paula Hernandez !


Don’t miss the ORS Debate, a key highlight of the #ORS2025 Closing Session! Experts @mmcgeelawrence and Nancy Lane will tackle a critical issue in #musculoskeletal research, moderated by @RyanET. Learn more: bit.ly/40HuaxE

Get there early! Given the state of affairs, I'm expecting a crowd for this #advocacy session at #ORS2025.
Hey #ORS2025 Attendees, The last two weeks have shown that we as scientists need to urgently join the conversation given the devastating disruptions to biomedical research 👇 Interested in learning more? Join our advocacy session this Saturday, February 8 from 12:45-1:45 PM.

Congratulations to @CharlesJYeoMD, Enterprise Chair of Surgery, on this well deserved recognition 👏 @TJUHospital @JeffersonUniv @KimmelCancerCtr
Congratulations to Dr. Charles J. Yeo, MD, from Thomas Jefferson University, Philadelphia, PA, on being named the 2025 Layton F. Rikkers Master Clinician Award Recipient! 🏅👏 Your commitment to clinical excellence sets a remarkable standard. #MasterClinician #SSATAwards

Going to be a great debate and fun time. Don’t miss it!
Don’t miss the ORS Debate, a key highlight of the #ORS2025 Closing Session! Experts @mmcgeelawrence and Nancy Lane will tackle a critical issue in #musculoskeletal research, moderated by @RyanET. Learn more: bit.ly/40HuaxE

Humacyte is proud to announce that the FDA has granted full approval for Symvess™, a first-in-class, universally implantable, bioengineered human vessel for extremity vascular trauma replacement and repair. This approval is a significant milestone in regenerative medicine, offering a new treatment option for patients with severe arterial injuries. Congratulations to our incredible team and partners who made this possible! Learn more at symvess.com See the Prescribing Information, including Boxed Warning: bit.ly/4dl5tuL INDICATION SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. IMPORTANT SAFETY INFORMATION BOXED WARNING: GRAFT FAILURE -Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage. CONTRAINDICATIONS DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries. WARNINGS & PRECAUTIONS -Graft Rupture: Vascular graft rupture has occurred in patients treated with SYMVESS. Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft rupture such as bleeding, pain and swelling in the extremity, or signs of extremity ischemia. Follow appropriate procedures for handling and administering SYMVESS. -Anastomotic Failure: Anastomotic failure has occurred in patients treated with SYMVESS. In clinical studies of SYMVESS, anastomotic failure occurred within the first 36 days post-implantation. Monitor patients for signs of anastomotic failure such as pain and swelling at the surgical site, decreasing hemoglobin or other signs and symptoms of bleeding. Advise patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding, swelling or worsening pain at the surgical site or changes in color of overlying skin. Follow appropriate procedures for handling and administering SYMVESS. -Thrombosis: Thrombosis has occurred in patients treated with SYMVESS. In clinical trials of SYMVESS, patients received antiplatelet therapy following implantation of SYMVESS to reduce the risk of thrombosis. The risk of thrombosis may increase in patients who discontinue antiplatelet therapy. Anti-platelet therapy is recommended following treatment with SYMVESS. -Transmission of Infectious Diseases: SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or infectious agents. The cells used in the manufacture of SYMVESS are derived from a donor who met the donor eligibility requirements for transmissible infectious diseases. Animal-derived reagents are tested for animal viruses, bacteria, fungi, and mycoplasma before use, but this does not eliminate the risk of transmitting these or other transmissible infectious diseases and disease agents. No transmissible agent infections have been reported during clinical testing. ADVERSE REACTIONS The most common adverse reactions (≥3%) were thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection. USE IN SPECIFIC POPULATIONS Pediatric Use: The safety and effectiveness of SYMVESS in pediatric patients (0 to 17 years old) have not been established. Geriatric Use: Two patients out of the 54 Extremity Group implanted with SYMVESS as a conduit in Study 1 were aged ≥65 years. The number of patients aged ≥65 years was not sufficient to determine whether they responded differently than younger patients to SYMVESS. #Humacyte #FDAApproval #RegenerativeMedicine #Innovation #Biotech #Firstinclass $HUMA

📢 #ORS2025 Open Door Call for Volunteers Due Today, Dec 18! Make an impact by guiding 7th and 8th-grade students from underrepresented backgrounds explore exciting futures in #STEM research on Feb 7 at the University of Arizona. Hurry, apply now: ors.org/opendoor/